EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2026-01-21
Management highlights
Jay Staley kicks off the call. George Gleason, Brannon Hamblen, Jake Munn, Tim Hicks, etc., participate. Key points include: Loan sale in the quarter was at par, not a strategy change; expect 2026 results to mirror 2024-2025, with CRE cycle nearing end, green shoots in leasing and refinances; Fed rate cuts aiding sponsors. Fee income is in early stages of growth with CIB loan syndication, mortgage, trust/wealth, private banking, and treasury management services expanding. Credit-wise, office shows liquidity and positive leasing trends, life sciences have challenges but improving with sponsor support. Buyback: Opportunistically bought shares below tangible book value, still have authorization left. Margin benefited from SOFR moves and managed deposit costs, with Q1 having a headwind from fewer days.
Guidance
2026 results expected to resemble 2024-2025; 2026 is near the end of the CRE cycle, optimistic about 2027. Loan growth guidance: More growth loaded in the final 3 quarters of the year.
Risks
Uncertainties in office and life sciences markets; potential sponsor support issues leading to asset resolution challenges; macroeconomic factors impacting CRE sponsors.
Q&A highlights
Q: Start with one kind of around the loan sale in the quarter and kind of your outlook on credit, net charge-offs and such. And maybe wondering what could lead you all to potentially lean further into the potential loan sales like you had on that 1 credit this quarter? And kind of given the commentary and the management comments around 2027 loss trends and a belief that those will improve kind of what gives you confidence to that end?
A: George and Brannon discuss loan sale at par, not strategy change, CRE cycle nearing end, green shoots in leasing, etc.
Q: I wanted to start on credit. You called out uncertainties, particularly in office and life sciences in the management comments. Can you give us some more color on what you're seeing there?
A: Brannon and George discuss office liquidity, life sciences slow rebound but improving, sponsor support.
Q: My first question's on the Boston property. It looks like in the third quarter, the reappraisal was done on an as-stabilized basis and implied a level that was much higher in 4Q, where it looks the appraisal was done now on an as-is basis. Can we just maybe talk through kind of what transpired between 3Q and 4Q that drove the more punitive appraisal?
A: George explains appraisal change due to sponsor support, collaborative with sponsors.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | — | — | — | — |
| Revenue | — | — | — | — |
Transcript
January 21, 2026Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.